NAC (N-Acety-L-cysteine)

Deep-dive

NAC is the acetylated form of L-cysteine. The acetyl group makes it more stable and less prone to oxidation during storage and digestion than plain cysteine. Once absorbed, deacetylation in the gut wall and liver liberates cysteine, which then enters the glutathione synthesis pathway as the rate-limiting substrate. Glutamate and glycine are abundant, cysteine is the bottleneck, which is the whole reason precursor loading works. Bioavailability of oral NAC is modest, around 4-10% reaches the systemic circulation intact, but enough cysteine is liberated en route to reliably raise tissue glutathione over days to weeks.

Beyond glutathione, NAC has two distinct mechanisms that matter clinically. The thiol group (-SH) directly reduces disulfide bonds, which is why it thins mucus, the cross-links holding mucus proteins together get cleaved. And NAC modulates the glutamate/cystine antiporter on glial cells, which raises extracellular glutamate and dampens synaptic glutamate release. That last mechanism is the basis for its psychiatric uses, which look nothing like an antioxidant story on the surface.

Liver and paracetamol. This is the most established use. IV NAC is the standard hospital antidote for paracetamol (acetaminophen) overdose and has been since the 1970s. Paracetamol is metabolised by the liver into a toxic intermediate called NAPQI, which is normally neutralised by glutathione. In overdose, glutathione gets depleted and NAPQI shreds hepatocytes. NAC replenishes the glutathione pool faster than NAPQI can do damage. Given within 8 hours of overdose it's almost completely protective, given within 24 hours it still substantially reduces mortality. Oral NAC at standard doses isn't a substitute for IV in an acute overdose, but for the more typical question of "I drink regularly and want to support my liver," it does meaningfully top up glutathione stores and helps the liver handle its normal detoxification load.

COPD and chronic bronchitis. NAC is the most-prescribed mucolytic globally for chronic respiratory conditions, and the evidence is reasonable. A 2024 meta-analysis of 20 trials found NAC reduced exacerbations in both COPD (24% reduction) and chronic bronchitis or pre-COPD (19% reduction), with improvements in symptoms and quality of life. An earlier 2015 meta-analysis covering 13 studies and 4,155 patients found a 25% reduction in exacerbations, with the protective effect more pronounced at doses above 600 mg/day. The dual mechanism here (thinning mucus through disulfide cleavage plus reducing oxidative inflammation in airway tissue) is well-matched to the disease. If you have a chronic productive cough, asthma with mucus issues, smoke or used to smoke, or just live in a polluted city and get bronchitis easily, this is the most defensible respiratory use.

Compulsive behaviours and psychiatric uses. The strongest psychiatric evidence is for what dermatology and psychiatry call body-focused repetitive behaviours, trichotillomania (hair-pulling), excoriation disorder (skin-picking), and onychophagia (nail-biting). A landmark 12-week RCT in 50 adults with trichotillomania titrated NAC from 1,200 to 2,400 mg/day and found significant reductions in hair-pulling severity. A 12-week trial in 66 adults with skin-picking disorder at 1,200-3,000 mg/day showed significant improvement on a modified Yale-Brown Obsessive Compulsive Scale. The mechanism here is the glutamate modulation, not antioxidant activity, NAC reduces compulsive glutamatergic drive in striatal circuits implicated in habit behaviours. For OCD proper, a multicentre RCT and other augmentation studies have been mixed, with some showing benefit when added to SSRIs and others showing nothing. Paediatric trichotillomania trials have also been negative. Conclusion: it's worth trying for adult body-focused repetitive behaviours and a reasonable augmentation in OCD, but not a first-line treatment.

PCOS and fertility in women. This is the female-relevant use with the most data. PCOS is partly driven by oxidative stress and insulin resistance, both of which NAC plausibly hits. A systematic review and meta-analysis of 8 trials in 910 women with PCOS found NAC significantly improved ovulation rates and pregnancy rates compared to placebo, though it was less effective than metformin. A larger 2022 meta-analysis of 18 trials in 2,185 women found benefit on ovulation and sex hormone profile, though the evidence base is mixed in quality. The most cited combination is NAC with inositol and folic acid, which has its own trial showing improved ovulation rate in PCOS with and without insulin resistance. Not every trial is positive, one IUI trial found no benefit when added to clomiphene plus letrozole, so it's not a guaranteed adjuvant, but the overall signal favours NAC as an inexpensive add-on for PCOS-related infertility. For women with PCOS not actively trying to conceive, the same antioxidant and insulin-sensitising rationale applies, though the data is thinner outside the fertility context.

Male fertility. Parallel logic, antioxidants reduce sperm DNA damage. Trials in men with idiopathic infertility show NAC at 600 mg/day for 3-6 months improves sperm motility, morphology, and pregnancy rates. The effect is most consistent when paired with

Selenium or

Zinc. If you're trying to conceive and have a sperm count, motility, or morphology issue on a semen analysis, this is one of the cheaper interventions worth running for a few months.

The GlyNAC longevity protocol. Out of Baylor College of Medicine, a research line argues that the most effective way to raise glutathione in older adults is to give both precursors, glycine and NAC together, at higher doses than most people use. A 16-week pilot in older adults found correction of glutathione deficiency, oxidative stress, mitochondrial fuel oxidation, inflammation, insulin resistance, endothelial dysfunction, cognition, and muscle strength. A 36-week extension trial replicated and extended these findings. A 2022 RCT in 114 healthy older adults confirmed dose-dependent rises in whole blood glutathione at GlyNAC doses from 2.4 to 7.2 g/day. The doses used are higher than most people take for NAC alone (100 mg/kg/day each of glycine and NAC, so roughly 7 g each for a 70 kg adult). This is the strongest evidence for NAC as an anti-aging compound, but it's specifically the precursor pair, not NAC alone.

Women. Most NAC research has either been done in women specifically (PCOS, fertility) or included them throughout. There's no female-specific dosing adjustment needed. Women in perimenopause and menopause tend to have lower baseline glutathione, partly because oestrogen helps maintain glutathione synthesis, so this group may notice more benefit from glutathione-raising strategies in general. The combination of NAC with

Inositol is the most evidence-backed female-specific protocol for PCOS and related insulin resistance. Pregnancy and breastfeeding: NAC has actually been studied in pregnancy for several indications (gestational diabetes, intrahepatic cholestasis, preeclampsia prevention) with reassuring safety, but routine supplemental use during pregnancy should still go through your obstetrician.

Older adults. Glutathione synthesis declines with age, and the response to precursor loading appears robust in this group. The GlyNAC trials specifically targeted older adults and show some of the most striking systemic improvements in the NAC literature, including muscle strength, walking speed, and cognitive measures. If you're over 60 and trying to pick one cheap upstream intervention with broad effects, the GlyNAC pairing has a stronger case than NAC alone.

Limitations of the evidence. The COPD and PCOS literature, while extensive, is dominated by short trials (3-6 months) and a fair amount of methodological heterogeneity. The longevity case rests almost entirely on the Baylor GlyNAC trials, which are small and from a single research group, important findings that need replication elsewhere. The psychiatric data is strongest for trichotillomania and excoriation, weaker and inconsistent for OCD. There's been longstanding speculation about NAC for COVID-19, neurodegeneration, and a long list of other conditions, the trial data here is mostly preliminary and shouldn't drive decisions.

Dosage:

• General antioxidant / liver support / daily use: 600-1,200 mg per day, taken as 600 mg once or twice daily. This is the dose used in most respiratory trials and the floor of most other uses. Effects on glutathione stores typically take 2-4 weeks to fully establish

• COPD / chronic bronchitis / mucus thinning: 600 mg twice daily (1,200 mg/day total). Higher doses up to 1,800 mg/day appear more effective at reducing exacerbations than the lower 600 mg/day dose. Take with water, increased fluid intake amplifies the mucolytic effect

• Trichotillomania / skin-picking / nail-biting: Start at 1,200 mg/day in two divided doses, titrate up to 2,400 mg/day after 4-6 weeks if no response. Give it at least 12 weeks before deciding it's not working. The benefit, when it appears, is gradual

• OCD augmentation: 2,400-3,000 mg/day in divided doses as an add-on to standard SSRI treatment. Don't expect a dramatic effect, results are mixed and modest

• PCOS: 1,200-1,800 mg/day, often combined with inositol (2-4 g/day of myo-inositol) and folic acid. Continue for at least 3-6 months for fertility outcomes

• Male fertility: 600 mg/day for 3-6 months, ideally stacked with selenium (100-200 mcg) or zinc (15-30 mg)

• GlyNAC longevity protocol: 100 mg/kg/day each of NAC and glycine, split into two doses morning and evening. For a 70 kg adult, that's about 3.5 g of each twice daily. This is significantly higher than the standalone NAC dose but is what the Baylor protocol uses

• Hangover prevention or recovery: 600-1,200 mg taken before or with alcohol, repeat the next morning. Won't make heavy drinking safe but does reduce the oxidative burden on the liver. Pairing with glycine and vitamin C is common

• Timing: Take with food if you get GI upset, otherwise empty stomach absorbs slightly better. NAC has a sulfur smell some people find unpleasant, capsules mask it better than powder

• Forms: Standard NAC capsules work fine. Effervescent NAC (the European pharmaceutical form, sold as Fluimucil or similar) is the most bioavailable oral form. Liposomal NAC exists but the evidence it outperforms standard isn't strong enough to justify the price. Avoid NAC sustained-release formulations, the data is on immediate-release

• Cycling: Not necessary. Glutathione synthesis has feedback inhibition built in, so once you've topped up the system, more NAC doesn't keep pushing it higher. Daily use is what the trials studied

Here's what you can expect:

Side effects & risks:

• GI side effects are the most common: nausea, bloating, occasional diarrhoea, sometimes a sulfur-related belching. Dose-dependent and usually resolves by taking with food, splitting the dose, or lowering it. Effervescent forms tend to be better tolerated than capsules at high doses

• Sulfur smell. NAC contains a thiol group and has a distinctive rotten-egg smell that's stronger than glutathione. Some people get sulfur-smelling sweat, breath, or urine. Harmless but unpleasant

• Asthma and inhaled NAC. Nebulised NAC can trigger bronchospasm in asthmatic patients and shouldn't be used without medical supervision. Oral NAC is generally fine for asthmatics and is actually used in some COPD-asthma overlap protocols, but if you have severe reactive airways, start low

• Headache, lightheadedness, or low blood pressure show up occasionally, especially at high doses (3,000+ mg/day) or with rapid IV administration. Oral doses rarely cause this

• Drug interactions. NAC's job is to support detoxification and modulate glutamate, which means it can theoretically interact with several drug classes. The most clinically relevant: nitroglycerin and other nitrates (NAC can amplify the hypotensive effect, problematic if you're on these for angina); carbamazepine (NAC can lower levels of this anticonvulsant); chemotherapy (the longstanding concern that antioxidants may protect tumour cells from oxidative chemotherapy damage, the evidence is mixed and oncology consensus is to discuss before using). Less concerning but worth noting: NAC may modestly enhance the effects of blood thinners like warfarin

• Heavy metal chelation. NAC binds heavy metals (mercury, cadmium, lead) and can mobilise them. For most people this is a non-issue, but at very high doses or in people with significant body burden, this can occasionally cause symptoms before excretion catches up. Most relevant for those already pursuing chelation protocols

• The cancer question. Same caveat as glutathione: because NAC reduces oxidative stress, there's a theoretical concern it could protect tumour cells from chemotherapy or radiation. Some animal studies have raised concerns about NAC accelerating metastasis in melanoma and lung cancer models, though the human relevance is unclear and the broader trial literature in cancer patients has been mixed. If you have an active cancer diagnosis, this is a conversation to have with your oncologist, not a self-managed supplement decision

• Hereditary kidney conditions and metabolic disorders. Rare contraindications: people with cystinuria (a genetic disorder of cysteine metabolism) should avoid NAC supplementation

• Pregnancy and breastfeeding. NAC has actually been studied in pregnancy more than most supplements (for paracetamol overdose treatment, gestational complications, and preeclampsia prevention) with reassuring safety, but routine elective supplementation during pregnancy should still go through your obstetrician

• Long-term safety data. Decades of clinical use at 600-1,800 mg/day for COPD, much of it spanning years, with a clean safety profile. The longer-term high-dose data (3,000+ mg/day chronically) is thinner but trials of 6-12 months at these doses have not flagged anything serious